GOSS
Gossamer Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.18
−0.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 53.3M | 48.5M | 114.7M | — | — |
| Cost of Revenue | 232.0K | 1.0M | — | — | — |
| Gross Profit | 53.1M | 47.5M | 114.7M | — | — |
| Operating Expenses | |||||
| R&D Expense | 171.4M | 174.1M | 138.5M | 135.3M | 170.9M |
| SG&A Expense | 47.9M | 37.6M | 36.1M | 38.5M | 47.6M |
| General & Admin Expense | 47.9M | 37.6M | 36.1M | 38.5M | 47.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (227.0K) | (1.0M) | — | 10.0M | 65.0K |
| Total Operating Expenses | 219.1M | 210.7M | 174.6M | 183.8M | 218.6M |
| Cost and Expenses | 219.4M | 211.7M | 174.6M | 183.8M | 218.6M |
| Operating Income (EBIT) | (166.1M) | (163.3M) | (59.9M) | (183.8M) | (218.6M) |
| Non-Operating | |||||
| Interest Income | 1.8M | 2.0M | 1.8M | 2.0M | 1.6M |
| Interest Expense | 11.0M | 11.0M | 11.5M | 13.5M | 13.9M |
| Net Interest Income | (9.2M) | (9.0M) | (9.7M) | (11.5M) | (12.3M) |
| Other Non-Op Income/Expense | 40.8M | (7.2M) | 4.3M | 3.9M | (10.8M) |
| Non-Operating Income (excl Interest) | 39.3M | (3.8M) | (15.8M) | (17.5M) | (3.1M) |
| EBT (Pre-Tax Income) | (125.3M) | (170.5M) | (55.6M) | (179.8M) | (229.4M) |
| Income Tax Expense | (88.0K) | (88.0K) | 893.0K | — | — |
| Bottom Line | |||||
| Net Income | (125.2M) | (170.4M) | (56.5M) | (179.8M) | (229.4M) |
| Earnings from Cont. Ops | (125.2M) | (170.4M) | (56.5M) | (179.8M) | (229.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (167.3M) | (170.4M) | (56.5M) | (179.8M) | (229.4M) |
| Per Share | |||||
| Basic EPS | ($0.57) | ($0.75) | ($0.25) | ($0.80) | ($2.84) |
| Diluted EPS | ($0.70) | ($0.75) | ($0.25) | ($1.18) | ($2.84) |
| Revenue Per Share | $0.23 | $0.21 | $0.51 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 234.1M | 228.5M | 226.2M | 225.6M | 84.6M |
| Diluted Shares Outstanding | 234.1M | 228.5M | 226.2M | 225.6M | 84.6M |
| Profitability Metrics | |||||
| EBITDA | (205.0M) | (158.5M) | (40.0M) | (161.9M) | (211.1M) |
| D&A | 717.0K | 1.0M | 4.2M | 4.4M | 4.4M |
| EBIT | (205.4M) | (159.5M) | (44.1M) | (166.3M) | (215.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026